Skip to main navigation Skip to search Skip to main content

Nanoparticle technologies for cancer therapy

  • Frank Alexis
  • , Eric M. Pridgen
  • , Robert Langer
  • , Omid C. Farokhzad
  • Massachusetts Institute of Technology
  • Brigham and Women's Hospital

Research output: Contribution to journalReview articlepeer-review

365 Scopus citations

Abstract

Nanoparticles as drug delivery systems enable unique approaches for cancer treatment. Over the last two decades, a large number of nanoparticle delivery systems have been developed for cancer therapy, including organic and inorganic materials. Many liposomal, polymer-drug conjugates, and micellar formulations are part of the state of the art in the clinics, and an even greater number of nanoparticle platforms are currently in the preclinical stages of development. More recently developed nanoparticles are demonstrating the potential sophistication of these delivery systems by incorporating multifunctional capabilities and targeting strategies in an effort to increase the efficacy of these systems against the most difficult cancer challenges, including drug resistance and metastatic disease. In this chapter, we will review the available preclinical and clinical nanoparticle technology platforms and their impact for cancer therapy.

Original languageEnglish
Pages (from-to)55-86
Number of pages32
JournalHandbook of Experimental Pharmacology
Volume197
DOIs
StatePublished - 2010
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Cancer therapy
  • Drug delivery
  • Metastatic cancer
  • Nanoparticle
  • Targeted

Fingerprint

Dive into the research topics of 'Nanoparticle technologies for cancer therapy'. Together they form a unique fingerprint.

Cite this